[Ischemic heart disease with low risk of vascular complications -- a novel indication for angiotensin converting enzyme inhibitors (results of EUROPA trial)].
Perepech
N B
NB
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017023:Coronary Angiography; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D020913:Perindopril / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D011379:Prognosis; D017257:Ramipril / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D010919:Placebos; D017257:Ramipril; D020913:Perindopril